CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
0.0951
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 5th, 9:11 AM EST
Detailed Quote
Previous Close
0.0951
Open
-
Bid
0.1167
Ask
0.1200
Day's Range
N/A - N/A
52 Week Range
0.0951 - 895.40
Volume
0
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
460,963
Chart
About CERo Therapeutics Holdings, Inc. - Common Stock (CERO)
CERo Therapeutics Holdings, Inc. is a biotechnology company that focuses on developing innovative therapies for serious medical conditions through advanced gene editing technologies. By leveraging proprietary platforms, the company aims to create transformative treatments that target the root causes of diseases, particularly in areas where current therapies are limited or lacking. CERo Therapeutics is dedicated to improving patient outcomes and advancing the field of precision medicine by working collaboratively with research institutions and healthcare professionals to ensure its solutions meet the highest standards of efficacy and safety. Read More
SOUTH SAN FRANCISCO, Calif, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the initiation of the second cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML). The first patient in the cohort (the fourth patient in the trial) received an initial dose of CER-1236 at twice the initial dose of the patients in the first cohort, with a follow-on second identical dose 48 hours later.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, announces that Chris Ehrlich, Chief Executive Officer will participate in a stem cell therapy panel titled, “A Space That is Ready to Have its Day,” at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
